| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 05/15/2024 | 9:00AM | Business Wire | Taro to Release Full Year Results on May 20, 2024 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 05/14/2024 | 8:20AM | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 05/08/2024 | 9:28AM | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 05/08/2024 | 9:07AM | Business Wire | Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 04/15/2024 | 8:00AM | Business Wire | Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd. | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 03/11/2024 | 6:19AM | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 02/15/2024 | 8:36AM | Edgar (US Regulatory) | Form SC 13E3 - Going private transaction by certain issuers | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/30/2024 | 1:18PM | PR Newswire (US) | Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law Firm | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/30/2024 | 7:00AM | PR Newswire (US) | Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/26/2024 | 9:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/25/2024 | 5:06PM | Business Wire | Taro Provides Results for December 31, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/19/2024 | 4:15PM | Business Wire | Taro to Release Third Quarter Results on January 25, 2024 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/17/2024 | 4:36PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/17/2024 | 4:35PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/17/2024 | 4:30PM | PR Newswire (Canada) | Taro Announces Merger Agreement with Sun Pharma | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/17/2024 | 4:30PM | PR Newswire (US) | Taro Announces Merger Agreement with Sun Pharma | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 01/04/2024 | 4:30PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 12/11/2023 | 4:31PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 12/11/2023 | 4:30PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 11/17/2023 | 4:30PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 10/27/2023 | 9:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 10/26/2023 | 5:00PM | Business Wire | Taro Provides Results for September 30, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 10/19/2023 | 4:30PM | Business Wire | Taro to Release Second Quarter Results on October 26, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 07/27/2023 | 10:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 07/26/2023 | 8:36PM | Business Wire | Taro Provides Results for the Quarter Ended June 30, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 07/19/2023 | 4:00PM | Business Wire | Taro to Release First Quarter Results on July 26, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 07/19/2023 | 7:00AM | PR Newswire (US) | Krensavage Asset Management Opposes Sun's Lowball Bid for Taro | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 06/30/2023 | 9:00AM | Business Wire | Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 06/29/2023 | 4:32PM | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |